Compare iShares MSCI India ETF (INDA) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Mesoblast Limited — how do they compare? iShares MSCI India ETF trades at $49.95, while Mesoblast Limited trades at $16.77 (market cap $2.21B). Which is the better fit depends on your goals.
| INDA | MESO | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $55.29 | $20.96 |
52-Week Low | $45.42 | $12.88 |
Market Cap | — | $2.21B |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $49.95, down 0.38% on the day, with technical indicators showing a bullish trend supported by moving averages but neutral oscillators. The ETF reflects exposure to India's economy, which grew 7.8% in Q1 2026 (CNBC, 2026-06-05), though financial ratios are unavailable. Recent news highlights sector-specific challenges, including IT weakness and pharmaceutical export hurdles.
The outlook for INDA is mixed, with India's robust economic growth offering long-term potential, but near-term risks from foreign outflows, geopolitical tensions, and sectoral headwinds may pressure performance. Investors should weigh macroeconomic resilience against volatility in key industries like technology and pharma.
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
